Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vifor Pharma
Biotech
Genexine's anemia drug matches Roche-CSL product in phase 3
The investigational chronic kidney disease drug candidate matched Roche and CSL Vifor’s Mircera in an interim look at phase 3 data.
Nick Paul Taylor
Apr 11, 2023 8:05am
Sanifit lands $231M Vifor buyout ahead of phase 3 data
Nov 22, 2021 6:08am
After COVID flop, Angion's leading med fails again
Oct 27, 2021 7:40am
Vifor doles out $55M upfront to license Travere's asset
Sep 16, 2021 11:41am
Vifor buys priority review voucher for vadadustat filing
Feb 18, 2020 8:12am
Vifor commits €25M to nephrology R&D joint venture with Evotec
Nov 6, 2019 8:41am
